Peritoneal Metastases: Can Cancer Spread Inside the Abdominal Cavity Be Treated?

Peritoneal metastases occur when cancer cells spread from their original location to the peritoneum — a thin membrane inside the abdomen that lines the abdominal wall and covers many abdominal organs. Cancer cells may form tumour deposits across different areas of the abdomen.

The condition is sometimes called peritoneal carcinomatosis, particularly when multiple tumour deposits are present. The term peritoneal metastases is preferred in modern clinical discussions because it describes the spread without implying a particular number or pattern of deposits.

Several cancers can spread to the abdominal lining. The treatment approach differs according to the primary site.

Colorectal cancer may spread to the peritoneum through direct extension, lymphatic or blood circulation, or by detaching from the original tumour. Peritoneal metastases may be detected at the time of first diagnosis or appear later. Selected patients may be assessed for cytoreductive surgery.

Ovarian cancer commonly involves the peritoneal surfaces. Treatment may include surgery and systemic chemotherapy. In selected circumstances, HIPEC may be considered as part of a specialist treatment strategy for carefully selected patients.

Gastric cancer can spread to the peritoneum. Some appendiceal tumours produce mucus that accumulates inside the abdomen (pseudomyxoma peritonei). Selected patients with appendiceal malignancies may be considered for cytoreductive surgery combined with HIPEC. Peritoneal metastases can also develop from pancreatic, gallbladder, bile duct, small bowel, endometrial and other cancers.

Peritoneal metastases often indicate metastatic disease. For many cancers, this corresponds to stage IV, but staging depends on the original tumour's classification system. A stage IV diagnosis does not automatically mean that no active treatment is possible. Some patients may be considered for treatment intended to achieve prolonged disease control or even curative intent in selected situations.

Some patients have no obvious symptoms during the early stages. Others develop abdominal or digestive problems.

Diagnosis involves confirming the presence of cancer, identifying its origin and determining how extensively it has spread. For international patients considering treatment in India, sharing previous reports and original imaging files before travel can help specialists assess what further investigations may be required.

The PCI is a scoring system used to assess the extent of tumour deposits within the abdominal cavity. The abdomen and pelvis are divided into 13 regions, each scored on the size of the largest deposit. Total scores range from 0 to 39. A higher score generally indicates greater disease burden.

Yes, treatment is possible for many patients. However, the appropriate treatment and its objectives vary significantly depending on the original cancer, disease extent and patient health.

Systemic chemotherapy uses medicines that circulate through the bloodstream. It may be used before surgery, after surgery, when surgery is not appropriate, or to control metastatic disease. The drug combination depends on the primary cancer and its molecular characteristics.

Targeted therapy works on specific molecular features of cancer. For example, colorectal cancer treatment may be guided by RAS, BRAF and HER2 status. Immunotherapy may benefit patients whose tumours are mismatch repair-deficient or microsatellite instability-high. Testing is necessary to establish whether these treatments are relevant.

Cytoreductive surgery aims to remove visible tumour deposits from the peritoneal surfaces. It may involve peritonectomy, omentectomy, bowel resection and removal of other involved structures. The aim is to achieve complete or near-complete removal of visible disease.

HIPEC stands for Hyperthermic Intraperitoneal Chemotherapy. It involves circulating heated chemotherapy inside the abdominal cavity, usually after cytoreductive surgery, to treat microscopic residual cancer cells. HIPEC is not suitable for every patient with peritoneal metastases. Its role varies by primary cancer, evidence base, disease burden and treatment protocol.

PIPAC (Pressurised Intraperitoneal Aerosol Chemotherapy) is a laparoscopic technique still under investigation for several cancer types. When surgery or other disease-directed treatments are unlikely to provide meaningful benefit, supportive and palliative care can help manage pain, ascites, nausea, bowel symptoms, nutrition, fatigue and emotional distress.

Cytoreductive surgery may be considered for carefully selected patients. The decision is based on the primary cancer type, disease distribution and location of deposits (not just total PCI), response to systemic therapy, small bowel involvement, disease outside the abdomen, and patient fitness. The 2025 consensus guideline emphasises early referral to a peritoneal surface malignancy centre and a selective approach to surgery.

No. CRS and HIPEC are related but distinct treatment components. CRS does not automatically require HIPEC. The evidence varies by cancer type. Selected patients with pseudomyxoma peritonei and advanced ovarian cancer may be assessed for CRS-HIPEC. Colorectal peritoneal metastases require careful consideration — the ASCO guideline recommends against adding oxaliplatin-based HIPEC to CRS in this setting. A specialist should explain the evidence for the patient's particular diagnosis.

India has specialist oncology services and teams involved in the management of selected peritoneal surface malignancies. The INDEPSO-ISPSM consensus recommendations address patient selection, diagnostic work-up, systemic treatment, surgery and follow-up for peritoneal malignancies.

There is no single cost for treating peritoneal metastases. The total expense depends on the original cancer, the treatment required and the patient's clinical condition. A patient receiving systemic chemotherapy may have a very different cost profile from someone undergoing extensive cytoreductive surgery with HIPEC.

Recovery depends on the treatment performed. After CRS-HIPEC, patients may require intensive care or high-dependency monitoring, pain management, intravenous fluids, nutritional support, monitoring of kidney function and blood counts, wound care, physiotherapy and gradual mobilisation. Some patients need several weeks to regain strength. Full recovery can take months. International patients should not plan their return journey around a fixed number of days.

Yes. Recurrence is possible after treatment, including after CRS-HIPEC. The risk depends on original cancer type, tumour biology, initial disease burden, completeness of surgery and response to systemic treatment. The treating team should provide a written follow-up plan — particularly important for patients returning to another country after treatment in India.

Patients from Tanzania, Kenya, Ethiopia, Uganda, Zambia, Nigeria, Iraq and other countries may consider India for specialist cancer assessment. For peritoneal metastases, it is particularly important to obtain a medical opinion before travelling because some treatment options involve complex surgery and prolonged recovery.

GAF Healthcare assists international patients with the coordination of medical treatment in India — including collection and organisation of medical reports, coordination of specialist consultations, hospital opinions and estimates, appointment coordination, medical visa documentation support, airport transfers, accommodation and interpreter arrangements. Clinical decisions remain with the treating doctors.

Medical Disclaimer: This article is for educational purposes only and does not replace medical consultation. It should not be used to make treatment decisions without advice from a qualified oncologist or surgical oncologist. Eligibility, prognosis and treatment costs must be assessed individually.